Prediction of risk for hepatocellular carcinoma by response of serum α-fetoprotein to entecavir therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 7, 2015, Pages 1175-1182

  Yang, Sung Wook ^a   Kim, Gi Hyun ^a   Chung, Jung Wha ^a   Sohn, Hyung Rae ^a   Lee, Sang Soo ^a   Hong, Sukho ^a   Chung, Seong Min ^a   Jang, Eun Sun ^a,b   Jeong, Sook Hyang ^a,b   Kim, Jin Wook ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Entecavir; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; ENTECAVIR; SERUM ALBUMIN; ANTIVIRUS AGENT; GUANINE; TUMOR MARKER;

ADULT; ALBUMIN BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CANCER RISK; CHRONIC HEPATITIS B; DISEASE COURSE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TERTIARY CARE CENTER; AGED; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; FORECASTING; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; MIDDLE AGED; RISK; TIME FACTOR;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; FORECASTING; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK; TIME FACTORS;

EID: 84931089430     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12921     Document Type: Article

References (28)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
2. European Association For The Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908-943.
3. Chen DS, Sung JL. Relationship of hepatitis B surface antigen to serum alpha-fetoprotein in nonmalignant diseases of the liver. Cancer 1979; 44: 984-992.
4. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989; 64: 2117-2120.
5. Lok AS, Lai CL. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9: 110-115.
6. Gish RG, Lok AS, Chang TT etal. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444.
7. Lai CL, Shouval D, Lok AS etal. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-1020.
8. Chang TT, Lai CL, Kew Yoon S etal. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430.
9. Zoutendijk R, Reijnders JG, Brown A etal. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011; 54: 443-451.
10. Chang TT, Liaw YF, Wu SS etal. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
11. Luo K, Liu Z, Karayiannis P. Effect of antiviral treatment on alfa-fetoprotein levels in HBV-related cirrhotic patients: early detection of hepatocellular carcinoma. J. Viral Hepat. 2010; 17: 511-517.
12. Wong GL, Chan HL, Tse YK etal. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 2014; 59: 986-995.
13. Kim GA, Seock CH, Park JW etal. Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. Liver Int. 2015; 35: 232-239.
14. Hosaka T, Suzuki F, Kobayashi M etal. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
15. Arends P, Sonneveld MJ, Zoutendijk R etal. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut 2014; doi: 10.1136/gutjnl-2014-307023. [Epub ahead of print].
16. Choi J, Kim JW, Seo JW etal. Implementation of consolidated HIS: improving quality and efficiency of healthcare. Healthc. Inform. Res. 2010; 16: 299-304.
17. Yoo S, Lee KH, Lee HJ etal. Seoul National University Bundang hospital's electronic system for total care. Healthc. Inform. Res. 2012; 18: 145-152.
18. Di Bisceglie AM, Sterling RK, Chung RT etal. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J. Hepatol. 2005; 43: 434-441.
19. Murashima S, Tanaka M, Haramaki M etal. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig. Dis. Sci. 2006; 51: 808-812.
20. Yao FY. Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis. J. Clin. Gastroenterol. 2003; 36: 440-442.
21. Shim JJ, Kim JW, Lee CK, Jang JY, Kim BH. Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2014; 29: 1699-1705.
22. Kobashi H, Miyake Y, Ikeda F etal. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol. Res. 2011; 41: 405-416.
23. Bolondi L, Sofia S, Siringo S etal. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-259.
24. Hann HW, Fu X, Myers RE etal. Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection - results from a clinic-based longitudinal cohort. Eur. J. Cancer 2012; 48: 2319-2327.
25. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 2007; 3: 79-87.
26. Bae SH, Yoon SK, Jang JW etal. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J. Korean Med. Sci. 2005; 20: 816-820.
27. Kim H, Jee YM, Song BC etal. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 2007; 50: 52-57.
28. Chan HL, Hui AY, Wong ML etal. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-1498.